Treatment of the first HIV positive patient in ABIVAX’s Phase IIa clinical trial with ABX464
In collaboration with the team of Professor Jamal Tazi at the CNRS in Montpellier, France, ABIVAX designed ABX464 to lead to a clinically relevant improvement in HIV therapy. ABX464 inhibits the biogenesis of viral RNA required for the replication of the HIV virus, a mechanism of action never before explored.
In pre-clinical reference models of HIV, ABX464 has proven its unique ability to induce a substantial reduction in viral load that persists for weeks after treatment arrest. Such an anti-viral effect has never been observed with existing treatments.
With current HIV treatments, the virus starts multiplying again as soon as the drugs are withdrawn, which typically means daily, life-long treatment for patients. Additionally, in pre-clinical tests, the HIV virus did not develop any resistance to ABX464. Pending confirmation in clinical trials, this unique mode of action and preclinical data to-date suggest that ABX464 could:
- Induce long term control of the viral load
- Not induce HIV mutants that are resistant to treatment
- Be less frequently administered over a shorter period than standard treatments; providing the potential to reduce healthcare costs and offer broader access to treatment
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.